

## LIST OF TABLES

No.	Title	Page
	<b>Introduction</b>	
2.5.1	Oral cancer incidence in G.C.R.I. by site [Hospital based Cancer registry, 2003].	16
2.6.1	Established risk factors for the development of oral cancer	19
2.8.1	Staging of Head and Neck cancer	25
2.10.1	Five-year relative survival rate by site and stage of disease	27
2.10.1	Five-year relative survival rate for different sites of oral cancer in percentage by stage of disease	27
	<b>Materials and Methods</b>	
3.1	Proforma seeking information of the subject's details	56
3.2	Details of controls and oral cancer patients	57
3.3	Clinical details of oral cancer patient	58
3.4	Methods used for analysis of parameters from blood and tissue samples of oral cancer patients	62
3.5	Antibodies used for the western blot assay	72
3.6	Working dilutions of 1 <sup>0</sup> and 2 <sup>0</sup> antibodies for different proteins by western blot procedure	76
3.7	The specified amount of reagents, standards and samples added in the ELISA	89
	<b>Results-4.1</b>	
4.1.1	Comparison of mean values of NFκBp65 activation in oral cancer tissues	92
4.1.2	Area under ROC curve for NFκBp65 in oral cancer patients	93
4.1.3	Frequency of NFκBp65 expression in malignant and adjacent normal oral tissues	94
4.1.4	Status of NFκBp65 activation with clinico-pathological variables in oral cancer patients.	94
4.1.5	Association of NFκBp65 activation with clinico-pathological variables in oral cancer patients by Multivariate analysis.	95
4.1.6	Correlation of NFκBp65 activation in malignant tissues with other parameters in oral cancer patients	96
4.1.7	Comparison of mean values of iNOS in oral cancer tissues	97
4.1.8	Frequency of iNOS expression in malignant and adjacent normal oral tissues	98
4.1.9	Area under ROC curve for iNOS in oral cancer patients	98

<b>4.1.10</b>	Association of iNOS expression with clinico-pathological variables in oral cancer patients by Multivariate analysis.	<b>99</b>
<b>4.1.11</b>	Comparison of mean values of Hsp-70 in oral cancer tissues	<b>101</b>
<b>4.1.12</b>	Frequency of Hsp-70 expression in malignant and adjacent normal oral tissues	<b>101</b>
<b>4.1.13</b>	Area under ROC curve for Hsp-70 expression in oral cancer patients	<b>102</b>
<b>4.1.14</b>	Association of Hsp-70 expression with clinico-pathological variables in oral cancer patients by Multivariate analysis.	<b>103</b>
<b>4.1.15</b>	Comparison of mean values of apoptotic proteins in oral SCC tissues	<b>104</b>
<b>4.1.16</b>	Frequency of bcl-2 and bax protein expression in malignant and adjacent normal oral tissues	<b>106</b>
<b>4.1.17</b>	Area under ROC curve for apoptotic protein expression in oral cancer patients	<b>106</b>
<b>4.1.18</b>	Unpaired analysis of Bcl-2, bax and bcl-2/bax ratio in malignant tissues with tumor size of oral cancer patients	<b>107</b>
<b>4.1.19</b>	Association of bcl-2 and bax expression in malignant tissues with clinico-pathological variables in oral cancer patients by Multivariate analysis	<b>107</b>
<b>4.1.20</b>	Comparison of mean values of Different forms of Gelatinase-A (MMP-2) in oral cancer tissues	<b>111</b>
<b>4.1.21</b>	Area under ROC curve for all forms of Gelatinase-A (MMP-2) in oral cancer patients	<b>112</b>
<b>4.1.22</b>	Association of Gelatinase-A (MMP-2) with Lymphatic response in oral cancer patients.	<b>113</b>
<b>4.1.23</b>	Comparison of Gelatinase-A (MMP-2) in oral SCC with Lymphatic response and larger tumor size.	<b>114</b>
<b>4.1.24</b>	Association of Gelatinase-A (MMP-2) with clinico-pathological variables in oral cancer patients by Multivariate analysis	<b>116</b>
<b>4.1.25</b>	Comparison of mean values of Different forms of Gelatinase-B (MMP-9) in oral SCC tissues	<b>117</b>
<b>4.1.26</b>	Area under ROC curve for all forms of Gelatinase-B (MMP-9) in oral cancer patients	<b>119</b>
<b>4.1.27</b>	Association of Gelatinase-B (MMP-9) in malignant tissues of oral SCC patients with clinico-pathological variables in oral cancer patients by Multivariate analysis	<b>119</b>
<b>4.1.28</b>	Comparison of latent and active forms of gelatinase-A (MMP-2) and -B (MMP-9) in oral lymph node tissues	<b>120</b>
<b>4.1.29</b>	Correlation of tissue levels of latent and active	<b>121</b>

	forms of gelatinase-A (MMP-2), gelatinase-B (MMP-9) in malignant tissues of oral cancer patients	
<b>4.1.30</b>	Comparison of mean values of gelatinase-A (MMP-2) and Gelatinase-B (MMP-9) in oral SCC tissues	<b>122</b>
<b>4.1.31</b>	Comparison of percentage activity of gelatinase-A (MMP-2) and gelatinase-B (MMP-9) in oral SCC tissues	<b>123</b>
	<b>Results-4.2</b>	
<b>4.2.32</b>	Frequency of serum p53 autoantibodies in subjects	<b>126</b>
<b>4.2.33</b>	Mean values of serum p53 autoantibodies in subjects	<b>126</b>
<b>4.2.34</b>	Area under ROC curve for serum p53 autoantibodies in subjects (controls vs oral cancer patients)	<b>128</b>
<b>4.2.35</b>	Frequency and association of serum p53 autoantibodies with tobacco habits in subjects	<b>128</b>
<b>4.2.36</b>	Mean values of serum p53 autoantibodies among tobacco users and nonusers of the subjects	<b>129</b>
<b>4.2.37</b>	Frequency of serum p53 autoantibodies in the oral cancer patients	<b>130</b>
<b>4.2.38</b>	Comparison of mean values of serum p53 autoantibodies between size of the tumor and stage of the disease	<b>130</b>
<b>4.2.39</b>	Univariate analyses for association of clinico-pathological parameters with the presence of serum p53 antibodies	<b>131</b>
<b>4.2.40</b>	Comparison of Mean values of serum p53 autoantibodies between pretreated and follow-up of the oral cancer patients	<b>132</b>
<b>4.2.41</b>	Comparison of Mean Values of serum IL-8 in subjects	<b>134</b>
<b>4.2.42</b>	Area under ROC curve for serum IL-8 in subjects (controls vs oral cancer patients)	<b>136</b>
<b>4.2.43</b>	Mean values of serum IL-8 among tobacco users and nonusers of the subjects	<b>136</b>
<b>4.2.44</b>	Comparison of mean values of serum IL-8 in oral cancer patients	<b>137</b>
<b>4.2.45</b>	Univariate analyses for association of clinico-pathological parameters with the presence of serum IL-8	<b>138</b>
<b>4.2.46</b>	Comparison of mean values of serum IL-8 between pretreated and follow-up of the oral cancer patients	<b>138</b>
<b>4.2.47</b>	Comparison of mean values of serum glycoprotein conjugates in subjects	<b>141</b>
<b>4.2.48</b>	Area under ROC curve for serum glycoprotein constituents in subjects (controls vs oral cancer	<b>142</b>

	patients)	
<b>4.2.49</b>	Mean values of serum glycoprotein constituents among tobacco user and nonusers of the subjects	<b>143</b>
<b>4.2.50</b>	Univariate analyses for association of clinico-pathological parameters with the presence of serum glycoprotein constituents	<b>145</b>
<b>4.2.51</b>	Comparison of mean values of serum glycoprotein constituents between pretreated (PT) and follow-up (CR and NR) of the oral cancer patients	<b>146</b>
<b>4.2.52</b>	Comparison of mean values of plasma MMP-2, TIMP-2, MMP-2/TIMP-2 and TIMP-2/MMP-2 in subjects	<b>149</b>
<b>4.2.53</b>	Area under ROC curve for plasma Gelatinase – A and its Tissue Inhibitor in subjects (controls vs oral cancer patients)	<b>150</b>
<b>4.2.54</b>	Comparison of mean values of plasma Gelatinase-A, TIMP-1, MMP-2/TIMP-2 and TIMP-2/MMP-2 among tobacco users and nonusers of the subjects	<b>151</b>
<b>4.2.55</b>	Association of Gelatinase-A (MMP-2) and its inhibitor TIMP-2 with clinico-pathological parameters in oral cancer patients by multivariate analyses	<b>152</b>
<b>4.2.56</b>	Comparison of mean values of plasma MMP-2, and its inhibitor TIMP-2 between untreated (PT) and follow-up (CR and NR) of the oral cancer patients	<b>153</b>
<b>4.2.57</b>	Comparison of mean values of plasma MMP-9, TIMP-1, MMP-9/TIMP-1 and TIMP-1/MMP-9 in subjects	<b>156</b>
<b>4.2.58</b>	Area under ROC curve for plasma Gelatinase - B and its Tissue Inhibitor in subjects (controls vs oral cancer patients)	<b>157</b>
<b>4.2.59</b>	Comparison of mean values of plasma Gelatinase-B, TIMP-1, MMP-9/TIMP-1 and TIMP-1/MMP-9 between tobacco users and nonusers of the subjects	<b>157</b>
<b>4.2.60</b>	Association of Gelatinase-B (MMP-9) with clinico-pathological parameters in oral cancer patients by multivariate analysis	<b>159</b>
<b>4.2.61</b>	Comparison of mean values of plasma MMP-9, and its inhibitor TIMP-1 between untreated (PT) and follow-up (CR and NR) of the oral cancer patients	<b>160</b>
<b>4.2.62</b>	Comparison of plasma levels of Gelatinase-A (MMP-2), Gelatinase-B (MMP-9) and their respective Tissue Inhibitors, TIMP-1, TIMP-2 with MMP/TIMP ratios in oral cancer patients	<b>164</b>
<b>4.2.63</b>	Correlation of plasma values of Gelatinase-A (MMP-2), Gelatinase-B (MMP-9) with their respective Tissue Inhibitors, TIMP-1, TIMP-2 with	<b>165</b>

<b>4.2.64</b>	MMP/TIMP ratios in oral cancer patients Area under ROC curve for blood antioxidant and detoxifying enzymes in subjects (controls vs oral cancer patients)	<b>168</b>
---------------	--	------------